RIGEL PHARMACEUTICALS INC
RIGLUS売上高
$294M
百万USD
営業利益
$125M
百万USD
純利益
$367M
百万USD
ROE
93.8%
最新FY
EPS
$19.48
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $81M | - | $0.22 |
| FY2021 | Q2 | $26M | - | $-0.08 |
| FY2021 | Q3 | $22M | $-21M | $-0.12 |
| FY2021 | FY | $149M | $-18M | $-0.11 |
| FY2022 | Q1 | $17M | $-27M | $-0.16 |
| FY2022 | Q2 | $30M | $-13M | $-0.08 |
| FY2022 | Q3 | $22M | $-19M | $-0.11 |
| FY2022 | FY | $120M | $-59M | $-0.34 |
| FY2023 | Q1 | $26M | $-14M | $-0.08 |
| FY2023 | Q2 | $27M | $-7M | $-0.04 |
| FY2023 | Q3 | $28M | $-6M | $-0.03 |
| FY2023 | FY | $117M | $-25M | $-0.14 |
| FY2024 | Q1 | $30M | $-8M | $-0.05 |
| FY2024 | Q2 | $37M | $-1M | $-0.06 |
| FY2024 | Q3 | $55M | $12M | $0.70 |
| FY2024 | FY | $179M | $17M | $0.99 |
| FY2025 | Q1 | $53M | $11M | $0.63 |
| FY2025 | Q2 | $102M | $60M | $3.28 |
| FY2025 | Q3 | $69M | $28M | $1.46 |
| FY2025 | FY | $294M | $367M | $19.48 |
| FY2026 | Q1 | $59M | $9M | $0.44 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $45M | $59M | $109M | $149M | $120M | $117M | $179M | $294M |
| 営業利益 | $-70M | $-80M | $-73M | $-69M | $-29M | $-12M | $-56M | $-20M | $24M | $125M |
| 純利益 | - | - | - | - | - | $-18M | $-59M | $-25M | $17M | $367M |
| 総資産 | $78M | $119M | $139M | $148M | $110M | $167M | $134M | $117M | $164M | $514M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $55M | $101M | $110M | $54M | $34M | $30M | $-14M | $-29M | $3M | $391M |
| 営業CF | - | $-78M | $-59M | $-42M | $-52M | $6M | $-74M | $-6M | $31M | $76M |
| EPS | - | - | - | - | - | $-0.11 | $-0.34 | $-0.14 | $0.99 | $19.48 |
| BPS | $0.45 | $0.68 | $0.66 | $0.32 | $0.20 | $0.18 | $-0.08 | $-0.16 | $0.18 | $21.19 |
| ROE | - | - | - | - | - | -59.0% | 430.2% | 87.6% | 531.8% | 93.8% |